Fundraising Fox

Awell

Founded 2017 · 29 employees on LinkedIn · 6 known investors

Awell provides a platform for building, automating, and orchestrating clinical care flows, using drag-and-drop or natural language AI prompts to design, deploy, and optimize workflows. It serves healthcare providers and care teams, connecting existing tools like EMRs, patient apps, and communication channels to coordinate tasks across staff, patients, and AI agents.

Also known as Awell Health

Investors · 6

Also in the syndicate · 1

Lord David Prior

Funding

SEC filings, press & company announcements

$5M disclosed across 1 of 2 rounds · 2023

Source: company announcements and press reports — follow each round's link for the claim.

Company profile

researched Aug 2026

Awell (Awell Health) offers a workflow-orchestration platform for healthcare delivery organisations, which it positions under the label "CareOps" — an analogue to DevOps applied to how care is designed, launched and continuously improved. The platform lets the staff closest to a clinical process build executable care flows without waiting on IT, either by drag-and-drop, by importing existing flowcharts, or by describing a flow in natural language for the system to generate. Builders can design forms, set if/then logic, automate calculations, run A/B tests and iterate on workflows in one environment.

Operationally, patients can be enrolled into care flows manually, via ADT feeds, spreadsheet uploads or automatically through webhooks. Awell then runs the workflow in the background, pushing tasks, insights and actions into the tools care teams already use, and engaging patients over SMS, email, AI agents or the organisation's own patient app. It coordinates tasks, priorities and timelines across nurses, care managers, patients and AI agents, and connects to EMRs, patient applications and communication platforms as connective tissue between existing systems. Analytics surface where workflows falter, with the option to connect data to the customer's own BI tools, and a chat interface to query care-flow metrics. AI capabilities include agents embedded into end-to-end workflows (for example reading faxes or calling patients with post-discharge instructions), form summarisation, message categorisation and voice AI, all with stated guardrails. The company states the platform is not itself intended to diagnose, treat or make patient-specific clinical decisions, and that clinical content and logic are created and governed by the customer organisation. Its earlier positioning described automating triage, patient onboarding and care plans, and synchronising data between systems to reduce clinician administrative burden.

Founding story

Founder and CEO Thomas Vande Casteele has described the company's motivation as the state of clinical workflows observed during hospitalisation — clinicians burdened with administrative work, patients using separate point solutions per condition, and care teams unable to keep pace with medical research; the company cites a study finding clinicians would need over 26 hours per day to follow national care guidelines for an average patient panel.

Business model

Business-to-business software sold to care delivery organisations and digital health companies, complemented by a hands-on "forward deployed" engagement model in which Awell staff work alongside customer teams, plus a bootcamp/education offering around CareOps.

Traction

Publicly disclosed traction is limited; the company references customers using the platform and lists customer-facing case material, and it was hiring product and outcomes engineering roles in the US as of the sources.

Latest developments

Recent site material centres on AI in care flows — natural-language care flow creation, AI agents that handle tasks such as reading faxes or placing post-discharge calls, conversational analytics over care flow metrics — alongside worklists, value-based care use cases and a CareOps Con event.

Full profile — market position, technology, go-to-market, geography, history, risks & controversies

Market position

Positions itself as an AI-powered CareOps platform and workflow-orchestration layer that sits across existing healthcare tooling rather than as a point solution or clinical decision-making system.

Emphasises orchestration across stakeholders rather than data-only automation, enabling non-engineering clinical staff to build and change workflows themselves, integration with incumbent systems so patients need not adopt new apps, and configurable AI agents inside end-to-end workflows with guardrails.

Technology

A no-code/low-code care flow builder (drag-and-drop, flowchart import, or natural language prompt generation) combined with an orchestration engine, patient enrolment via ADT feeds, spreadsheet upload or webhooks, multi-channel patient communication (SMS, email, patient apps, voice AI), integrations with EMRs and communication platforms, embedded AI agents, analytics with BI connectivity, and a developer hub and API layer.

Go-to-market

Direct sales via booked calls and demos, a developer hub and help centre for technical adopters, content marketing through a blog and use-case pages, a bootcamp programme, and a company-run event, CareOps Con. Following its 2023 seed round the company said it would build relationships with traditional care organisations in the United States.

Healthcare providers and care organisations, including traditional care organisations and digital health companies, with users spanning nurses, care managers and other care team members as well as developers.

Geography

Reported as Brussels-based at the time of its 2023 seed round, with stated expansion focus on the United States; open roles are listed as remote in the US.

History

The company positions its origin around the belief that care delivery is slow, siloed and reliant on spreadsheets. In September 2023 it announced a $5 million seed round led by Octopus Ventures to grow the team, invest in R&D and expand to the US market. As of 2025 its site markets a CareOps platform spanning care flow design, operations, analytics and AI agents, with products including worklists, agents and value-based care use cases.

Risks & controversies

The company states its platform is not intended to diagnose, treat or make patient-specific clinical decisions and that clinical content and logic remain the responsibility of the customer organisation; it references HIPAA compliance, a trust and compliance programme and a responsible disclosure programme.

Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
HeadcountAug 202629

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Timeline · 2

launches, deals, and filings
Sep 2023
Awell raises $5M seed round led by Octopus Ventures

Awell announced a $5 million seed round led by Octopus Ventures with participation from S16 and angel investors including Lord David Prior, former chair of the UK's NHS. Proceeds earmarked for team growth, R&D and product development.

$5M source ↗

Sep 2023
US market expansion targeted following seed round

Alongside its seed round, the Brussels-based company said it would target expansion into the United States, focusing on building relationships with traditional care organisations.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

In the news

Research sources · 6

primary sources listed
  • Awellawellhealth.com · web

6 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Awell do?
Awell is a CareOps platform for designing, automating and orchestrating clinical care flows across care teams, patients and AI agents.
Who are Awell's investors?
Awell's investors include KAYA, Moonfire Ventures, Octopus Ventures, LocalGlobe, s16.
How much funding has Awell raised?
Awell has disclosed $5M raised across 1 of its 2 known rounds.